PMID- 34042339
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 17
IP  - 740
DP  - 2021 May 26
TI  - [Practical considerations in the use of SGLT2 inhibitors in cardiovascular 
      diseases].
PG  - 1034-1038
AB  - Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs which 
      offer cardiovascular (CV) and renal benefits. They are currently indicated as 
      first-line treatments of type 2 diabetes mellitus (T2DM) in patients with CV 
      disease, high CV risk, renal disease, or heart failure with reduced ejection 
      fraction (HFrEF). Two randomized clinical trials have shown the benefits of 
      dapagliflozin and empagliflozin in patients with HFrEF, regardless of the 
      presence of T2DM. Despite an overall favorable safety profile, attention has to 
      be paid to adverse events, such as an increased risk of euglycemic diabetic 
      ketoacidosis and genital mycotic infections. We present an up-to-date narrative 
      literature review of the physiological mechanisms of action, current indications, 
      and side effects of SGLT2 inhibitors.
FAU - Lu, Henri
AU  - Lu H
AD  - Service de cardiologie, CHUV, 1011 Lausanne.
FAU - Hullin, Roger
AU  - Hullin R
AD  - Service de cardiologie, CHUV, 1011 Lausanne.
FAU - Yerly, Patrick
AU  - Yerly P
AD  - Service de cardiologie, CHUV, 1011 Lausanne.
FAU - Meyer, Philippe
AU  - Meyer P
AD  - Service de cardiologie, HUG, 1211 Geneve 14.
FAU - Kosinski, Christophe
AU  - Kosinski C
AD  - Service d'endocrinologie, diabetologie et metabolisme, CHUV, 1011 Lausanne.
FAU - Daux, Aurelien
AU  - Daux A
AD  - Service de cardiologie, CHUV, 1011 Lausanne.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Considerations pratiques pour l'utilisation des inhibiteurs du SGLT2 dans les 
      maladies cardiovasculaires.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Benzhydryl Compounds/adverse effects
MH  - *Cardiovascular Diseases/chemically induced
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Heart Failure
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Stroke Volume
COIS- Le Dr Philippe Meyer a participe a des presentations et des conseils consultatifs 
      organises par Bayer dont les honoraires ont ete integralement verses a la 
      Fondation pour la recherche de la cardiologie universitaire de Geneve (GEcor). 
      Les autres auteurs n'ont declare aucun conflit d'interets en relation avec cet 
      article.
EDAT- 2021/05/28 06:00
MHDA- 2021/05/29 06:00
CRDT- 2021/05/27 09:05
PHST- 2021/05/27 09:05 [entrez]
PHST- 2021/05/28 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
AID - RMS0740-006 [pii]
PST - ppublish
SO  - Rev Med Suisse. 2021 May 26;17(740):1034-1038.